GIGABYTE
17.5.2023 03:31:33 CEST | Business Wire | Press release
GIGABYTE, a leading innovator of computer hardware and server solutions, announces its unprecedented exhibits at COMPUTEX 2023. Resonating its theme “Future of COMPUTING”, GIGABYTE is unveiling its all-around technical achievements, including industry-leading AI/HPC servers, green computing solutions, gaming and creator products, industrial PC, AI smart securities, and autonomous vehicle technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005112/en/
GIGABYTE to Introduce Leading-Edge AI Solutions and Computers at COMPUTEX 2023, Unveiling “Future of COMPUTING” (Graphic: Business Wire)
Besides product exhibits, GIGABYTE will hold a four-day Tech Talk with speakers from AMD, Ampere, Intel, and NVIDIA, sharing insights about how the future of computing is reshaping the technology landscapes. The exhibition will be held from May 30th to June 2nd on the 1st floor, Taipei Nangang Exhibition Center, Hall 1.
Take the Lead in the AI Era with GIGABYTE’s Trailblazing GPU/HPC Servers
The emergence of ChatGPT and various generative AI applications are making huge waves of industry evolution, driving all-time demand for AI computing servers. At COMPUTEX, GIGABYTE and its subsidiary, Giga Computing, are unveiling a cutting-edge lineup of GPU-accelerated servers and HPC servers. These solutions are aimed at accelerating exascale data analysis, deep learning, machine learning, inferencing, large language models (LLM), and generative AI training tasks, unlocking the unparalleled breakthroughs of AI development.
The latest lineup of GPU/HPC server solutions is powered by the latest CPU platform, GPU accelerator cards, and AI deep learning and inference technologies from leading tech partners. With GIGABYTE’s exclusive density-optimized server design and cooling technology, AI computing servers can achieve superior performance and energy efficiency, allowing enterprises and institutes to become the front-runner in AI competition.
Strike the Goals of Data Center Sustainability with GIGABYTE’s Immersion Cooling Solutions
The advent of AI technology has raised concerns about surging electricity consumption and carbon emissions, leading to the growing demand for data center cooling solutions designed to save power, boost computing performance, and reduce total cost of ownership (TCO). For the first time, GIGABYTE is showcasing three models of immersion cooling tanks and corresponding server series, demonstrating its widely acclaimed green computing solutions at COMPUTEX.
GIGABYTE's immersion cooling solutions have established admirable standards in energy efficiency and cost-effectiveness; therefore, they have been adopted by global semiconductor giants, telecommunication services, and European top research centers. GIGABYTE’s self-developed total solutions include the immersion cooling tanks, server configuration designs, and automatic monitoring and adjustment mechanisms, allowing enterprises and institutions to embrace sustainability and achieve innovation breakthroughs.
Explore the Gaming and Creator Computers with Lightspeed Overlocking
In addition to enterprise solutions, GIGABYTE is exhibiting a comprehensive computer portfolio, including the 2023 Red Dot Design Award-winning AORUS and AERO motherboards, graphics cards, and laptops, as well as STEALTH 500 computer assembly kit that won CES Innovation Award, SSD and large-size 4K monitors. All of these demonstrate GIGABYTE’s technical prowess and exceptional aesthetics. Tech enthusiasts at the booth will be thrilled to explore how GIGABYTE’s computers are pushing the performance beyond the limits and offering immersive experiences.
Grasp the Insights of Industry-Leading AI Trends at GIGABYTE Tech Talk
During the four-day COMPUTEX exhibition, GIGABYTE’s booth is holding Tech Talk sessions with diverse topics. Speakers from technology giants will share first-hand insights of AI advancements and green computing technologies, delivering various perspectives of “Future of COMPUTING” to the audiences.
Visit GIGABYTE’s COMPUTEX event page.
Subscribe to GIGABYTE newsletter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom